FDA establishment 1819470, Indianapolis, Indiana, United States. Part of Eli Lilly's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations, and the shipments FDA refused at the border.
FY2018 to FY2027 to date; 0 classified OAI
A hatched bar is a year that is not over, so its count covers only part of the year.
Inspections citing each reference
| Ended | Product and area | Citations | Classification |
|---|---|---|---|
| Jan 9, 2026 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| May 20, 2025 | Drugs · Drug Quality Assurance | None posted | Voluntary Action Indicated (VAI) |
| Mar 27, 2025 | Drugs · Bioresearch Monitoring | None posted | Voluntary Action Indicated (VAI) |
| Jan 15, 2025 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Sep 15, 2023 | Drugs · Bioresearch Monitoring | 5 cited references
| Voluntary Action Indicated (VAI) |
| May 18, 2023 | Devices · Compliance: Devices | None posted | No Action Indicated (NAI) |
| Sep 30, 2022 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Jan 13, 2022 | Drugs · Bioresearch Monitoring | None posted | Voluntary Action Indicated (VAI) |
| Mar 16, 2021 | Drugs · Drug Quality Assurance | None posted | Voluntary Action Indicated (VAI) |
| Mar 20, 2020 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Jan 17, 2020 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Mar 5, 2019 | Devices · Compliance: Devices | None posted | No Action Indicated (NAI) |
| Jan 25, 2019 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Apr 23, 2018 | Drugs · Bioresearch Monitoring | 1 cited reference
| Voluntary Action Indicated (VAI) |
| Oct 6, 2017 | Devices · Postmarket Assurance: DevicesDevices · Compliance: Devices | None posted | No Action Indicated (NAI) |
| Jul 28, 2017 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| May 25, 2017 | Drugs · Drug Quality Assurance | None posted | No Action Indicated (NAI) |
| Jul 20, 2016 | Drugs · Drug Quality AssuranceDrugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Jun 10, 2016 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| May 13, 2016 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Aug 4, 2015 | Drugs · Drug Quality Assurance | None posted | No Action Indicated (NAI) |
| May 12, 2015 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Feb 11, 2015 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| May 8, 2014 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Dec 12, 2013 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Dec 6, 2013 | Devices · Compliance: DevicesDevices · Postmarket Assurance: Devices | None posted | Voluntary Action Indicated (VAI) |
| Apr 19, 2013 | Drugs · Drug Quality Assurance | None posted | Voluntary Action Indicated (VAI) |
| Feb 14, 2013 | Drugs · Bioresearch Monitoring | None posted | Voluntary Action Indicated (VAI) |
| Dec 14, 2012 | Drugs · Bioresearch Monitoring | None posted | Voluntary Action Indicated (VAI) |
| Sep 29, 2011 | Drugs · Bioresearch Monitoring | None posted | No Action Indicated (NAI) |
| Aug 23, 2011 | Drugs · Drug Quality AssuranceDevices · Compliance: Devices | None posted | Voluntary Action Indicated (VAI) |
| Sep 3, 2010 | Drugs · Bioresearch Monitoring | 2 cited references
| Voluntary Action Indicated (VAI) |
| Jul 28, 2010 | Drugs · Drug Quality Assurance | 2 cited references
| Voluntary Action Indicated (VAI) |
| Sep 22, 2009 | Drugs · Drug Quality Assurance | None posted | No Action Indicated (NAI) |
| Product | Charges | Latest |
|---|---|---|
| DULAGLUTIDEOther · 58HCL06 | Sep 18, 2026 | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCK74 | Aug 14, 20263 lines | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCK74 | Jul 21, 2026 | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PDY74 | Apr 17, 20262 lines | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCP74 | Apr 2, 2026 | |
| SOMATROPINOther · 58HCY05 | Mar 12, 2026 | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCP74 | Jan 14, 2026 | |
| INSULIN GLARGINEOther · 58HCP09 | Nov 4, 20255 lines | |
| ENDOCRINE-METABOLIC AGENT, NECOther · 58HCP99 | Nov 4, 20254 lines | |
| LISPRO INSULIN (ANTI-DIABETIC)Drugs · 61PCP54 | Nov 4, 2025 | |
| IXEKIZUMABOther · 58MCP11 | Nov 3, 20252 lines | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCY74 | Oct 23, 20255 lines | |
| BARICITINIB (ANTI-RHEUMATIC)Drugs · 62QCE05 | Sep 12, 2025 | |
| EMPAGLIFLOZIN (ANTI-DIABETIC)Drugs · 61PDY73 | Jun 23, 2025 | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCK74 | Jun 6, 2025 | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PDK74 | May 7, 2025 | |
| TIRZEPATIDE (ANTI-DIABETIC)Drugs · 61PCL74 | Aug 27, 2024 | |
| FLUOXETINE (ANTI-DEPRESSANT)Drugs · 61NCA29 | Jul 5, 2024 |
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. FDA Data Dashboard and warning letters
Indianapolis, Indiana, United States. Part of